HSPA5 and prostate carcinoma: In vivo, antibodies against HSPA5 were found in the circulation of prostate cancer patients [143], and targeting HSPA5 in the surface of tumor cells by the use of chimeric peptides composed of HSPA5 binding motifs fused to a programmed cell death-inducing sequence reduced the tumor growth in preclinical animal models of prostate and breast cancer [144].